LONDON, UK – Thursday 23 July, 2015 – Immodulon Therapeutics, a privately held, late-stage biopharmaceutical company focused on immuno-oncology, has made a new senior appointment to its Board ofDirectors to support its continued growth and development.
Dr James Shannon brings 30 years’ experience to Immodulon working in senior positions in the pharmaceutical industry, including Chief Medical Officer at GlaxoSmithKline and Global Head of Drug Development for Novartis. Dr Shannon joins Immodulon as non-executive director with immediate effect.
Immodulon Chairman, Charles Akle, commented: “James will bring a wealth of clinical development and regulatory experience and insight to the Immodulon Board as we focus on our future development and progress towards Phase III of our lead product, IMM-101, in pancreatic cancer. We look forward to benefitting from his experience and counsel.”
In Dr Shannon’s roles at GlaxoSmithKline and Novartis he was very involved in bringing highly innovative oncology products to the market. He has also served on the boards of a number of smaller biopharmaceutical companies. He is trained in Medicine and Cardiology, received undergraduate and graduate degrees at Queen’s University Belfast and is a member of the Royal College of Physicians (UK).
Dr Shannon said: “Immodulon has achieved a remarkable amount in a short period of time and generated some intriguing clinical data. I look forward to working with the team there as they guide IMM-101 through the next stages of its development towards the ultimate goal of making this potentially important therapy available for patients.
Immodulon Therapeutics Ltd is a privately owned, UK-based biopharmaceutical company focused on developing systemic immunomodulators as potential treatments for a range of cancers. Immodulon’s lead product, IMM-101, has shown clinically significant improvements in survival in metastatic pancreatic cancer in Phase 2 studies without increasing toxicity.